CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 300 enrolled
Drug / intervention
Tenecteplasedrug
Likely dose
Tenecteplase 0.25mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03340493
NCT03340493Phase 2Completed
CompareCT.gov

EXTEND-IA TNK: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase Part 2

Neuroscience Trials Australia·interventional·Posted Nov 13, 2017·Updated Mar 4, 2020

In Brief

A Phase 2 clinical trial evaluating Tenecteplase for Ischemic Stroke. Completed, enrolled 300 participants across 28 sites in 2 countries.

Detailed Summary

Patients presenting to the emergency department with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to either 0.4mg/kg or 0.25mg/kg intravenous tenecteplase before all participants undergo endovascular thrombectomy. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesAustralia, New Zealand
CollaboratorsThe Florey Institute of Neuroscience and Mental Health

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 13, 2017
Enrollment StartDec 6, 2017
Primary CompletionJul 23, 2019
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.6 years ago

Interventions

Tenecteplasedrug

Tenecteplase 0.25mg/kg and 0.4mg/kg are being used